Allarity Therapeutics Inc(ALLR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALLR Allarity Therapeutics Inc

Post-Mkt 04-14 17:02:44 EDT

1.19

+0.00

0.00%

盘后1.22

+0.03+2.52%

16:57 EDT

High1.22	Low1.15	Vol129.28K
Open1.18	D1 Closing1.19	Amplitude5.88%
Mkt Cap18.82M	Tradable Cap18.79M	Total Shares15.82M
T/O152.87K	T/O Rate0.82%	Tradable Shares15.79M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALLR","market":"US","secType":"STK","nameCN":"Allarity Therapeutics Inc","latestPrice":1.19,"timestamp":1776196800000,"preClose":1.19,"halted":0,"volume":129284,"hourTrading":{"tag":"盘后","latestPrice":1.22,"preClose":1.19,"latestTime":"16:57 EDT","volume":233,"amount":277.3000104,"timestamp":1776200235176,"change":0.03,"changeRate":0.02521,"amplitude":0.02521},"delay":0,"changeRate":0,"floatShares":15794100,"shares":15818980,"eps":-0.78,"marketStatus":"Post-Mkt","change":0,"latestTime":"04-14 17:02:44 EDT","open":1.18,"high":1.22,"low":1.15,"amount":152874.3997664,"amplitude":0.058824,"askPrice":1.22,"askSize":101,"bidPrice":1.09,"bidSize":35,"shortable":3,"etf":0,"ttmEps":-0.78,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1776211200000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":1.19,"preHourTrading":{"tag":"盘前","latestPrice":1.2209,"preClose":1.19,"latestTime":"08:58 EDT","volume":127,"amount":153.5963908,"timestamp":1776171527734,"change":0.0309,"changeRate":0.025966,"amplitude":0.045042},"postHourTrading":{"tag":"盘后","latestPrice":1.22,"preClose":1.19,"latestTime":"16:57 EDT","volume":233,"amount":277.3000104,"timestamp":1776200235176,"change":0.03,"changeRate":0.02521,"amplitude":0.02521},"volumeRatio":0.959722},"requestUrl":"/m/hq/s/ALLR/tweets","defaultTab":"tweets","newsList":[{"id":"2626174143","title":"Allarity Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2626174143","media":"Reuters","labels":["conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626174143?lang=en_us&edition=fundamental","pubTime":"2026-04-11 05:19","pubTimestamp":1775855991,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics scheduled 2026 annual shareholder meeting for June 26, 2026 in virtual format.Shareholders will vote to elect Class I director nominee Jesper Hoiland to a term ending at 2029 annual meeting.Ballot includes proposal to expand 2021 equity incentive plan share pool to 2,021,990 shares from 1,521,990 shares.Meeting agenda also includes advisory vote on executive pay, approval to issue additional common shares under Tumim Stone Capital purchase agreement, plus amendment to limit liability of certain officers.Shareholders will also vote on auditor appointment ratification for fiscal 2026, plus authority to adjourn meeting to solicit additional proxies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL4xdtBg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623757581","title":"BRIEF-Allarity Therapeutics Reports Full Year 2025 Financial Results And Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2623757581","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623757581?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:48","pubTimestamp":1774961289,"startTime":"0","endTime":"0","summary":"BRIEF-Allarity Therapeutics Reports Full Year 2025 Financial Results And Corporate ProgressAllarity Therapeutics Inc ALLR.O:ALLARITY THERAPEUTICS REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND CORPORATE PROGRESSSource text: ID:nGNX55ZlGYFurther company coverage: ALLR.O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUA9L1FSP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623324559","title":"Allarity FY25 net loss narrows to $11 million; revenue rises to $0.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623324559","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623324559?lang=en_us&edition=fundamental","pubTime":"2026-03-31 05:31","pubTimestamp":1774906299,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics posted net loss of $11.2 million for fiscal 2025, narrowing from $24.5 million a year earlier.Revenue was $0.3 million, compared with no revenue in 2024.Operating loss tightened to $12.6 million on total operating costs and expenses of $12.9 million.Cash ended 2025 at $14.7 million, while cash used in operating activities was $14.8 million.Allarity said it is now focused on stenoparib and its companion diagnostic, expecting current cash to fund operations for at least the next 12 months from the date of the annual report.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and R","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL8757wX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622465822","title":"Allarity Therapeutics Inc  expected to post a loss of 22 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622465822","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622465822?lang=en_us&edition=fundamental","pubTime":"2026-03-27 21:33","pubTimestamp":1774618389,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics Inc  expected to post a loss of22cents a share - Earnings Preview Allarity Therapeutics Inc ALLR.OQ ALLR.O is expected to  report resultson March 31 (estimated) for the period en","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F18A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617680042","title":"Allarity Therapeutics Closes $20 Million Non-Convertible Debt Financing With Streeterville Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2617680042","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617680042?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:01","pubTimestamp":1772802073,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics said it closed a $20 million non-convertible debt financing with Streeterville Capital through a note purchase agreement. The company issued two promissory notes with original principal amounts of $10.93 million and $10.0 million, and said the proceeds are expected to extend its cash runway into summer 2028 and support completion of its Phase 2 ovarian cancer trial and advancement of stenoparib toward pivotal development and commercialization.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL9yWsZn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","SG9999014013.SGD","BK4588","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4585","BK4139","LU2210150020.SGD","SG9999014005.SGD","SG9999014021.USD","ALLR","LU2210149790.SGD","NDAQ","BK4112","SG9999014039.USD","LU0314104364.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617213680","title":"BRIEF-Allarity Therapeutics Closes $20 Million Financing To Accelerate The Advance Of Stenoparib Toward FDA Approval And Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2617213680","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617213680?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:01","pubTimestamp":1772802063,"startTime":"0","endTime":"0","summary":"BRIEF-Allarity Therapeutics Closes $20 Million Financing To Accelerate The Advance Of Stenoparib Toward FDA Approval And CommercializationMarch 6 (Reuters) - Allarity Therapeutics Inc ALLR.O:ALLARITY ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nTUA9BJ2W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617802496","title":"Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2617802496","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617802496?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:00","pubTimestamp":1772802001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nTUA9BJ2W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612944501","title":"Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Relapsed SCLC Trial of Stenoparib Plus Temozolomide","url":"https://stock-news.laohu8.com/highlight/detail?id=2612944501","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612944501?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:15","pubTimestamp":1771420528,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics Inc. reported that the first patients have been dosed in a U.S. Department of Veterans Affairs-funded, investigator-initiated Phase 2 trial evaluating stenoparib , a dual PARP and WNT pathway inhibitor, in combination with temozolomide for relapsed small cell lung cancer. The study is open for enrollment across 11 VA medical centers in the United States. No clinical results were presented in the announcement; results are expected to be reported in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL15vmqR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","NDAQ","SG9999014021.USD","SG9999014039.USD","BK4588","SG9999014005.SGD","LU2210149790.SGD","BK4585","LU0314104364.USD","IE00B3QW5Z07.USD","BK4112","LU2210150020.SGD","IE00BKPKM429.USD","IE00B64PRP62.GBP","ALLR","BK4139","IE00BGHQF748.EUR","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612446649","title":"Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need","url":"https://stock-news.laohu8.com/highlight/detail?id=2612446649","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612446649?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:15","pubTimestamp":1771420500,"startTime":"0","endTime":"0","summary":"Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung CancerTrial is fully funded by the U.S. Department of Veterans Affairs and is open for enrol","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/18/3240189/0/en/Allarity-Therapeutics-Doses-First-Patients-in-VA-Funded-Phase-2-Trial-Focused-on-Small-Cell-Lung-Cancer-with-High-Unmet-Need.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","LENZ","BK4139","ALLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611908289","title":"Allarity Therapeutics Inc - Prospectus for Resale of 255,103 Shares of Common Stock by Selling Stockholder - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2611908289","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611908289?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:38","pubTimestamp":1770932328,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nFWN3Z81NT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608987871","title":"Allarity announce enrollment open for Phase 2 trial of stenoparib, temozolomide","url":"https://stock-news.laohu8.com/highlight/detail?id=2608987871","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608987871?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:20","pubTimestamp":1770124833,"startTime":"0","endTime":"0","summary":"Allarity (ALLR) Therapeutics announced that enrollment is now open for its new Phase 2 clinical trial evaluating the combination of stenoparib and ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/allarity-announce-enrollment-open-for-phase-2-trial-of-stenoparib-temozolomide-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/allarity-announce-enrollment-open-for-phase-2-trial-of-stenoparib-temozolomide-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ALLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608879859","title":"Allarity Therapeutics Announces That Its Collaborative Phase 2 Trial With the United States Veteran’s Administration Combining Stenoparib With Temozolomide in Relapsed Small Cell Lung Cancer Is NOW Open for Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2608879859","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608879859?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123652,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YZ02Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608005876","title":"Allarity Therapeutics Partners with U.S. Department of Veterans Affairs for Phase 2 Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2608005876","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608005876?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123629,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics Inc. has entered into a collaboration with the U.S. Department of Veterans Affairs  to conduct a Phase 2 clinical trial evaluating the combination of stenoparib and temozolomide for the treatment of recurrent small cell lung cancer . The trial, fully funded by the VA's Special Emphasis Panel on Precision Oncology, is now open for enrollment at 11 VA sites across the United States. This partnership aims to explore the potential benefits and improved safety profile of stenoparib in combination regimens for patients with relapsed SCLC, particularly among veterans who have limited treatment options.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL67nJML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2210149790.SGD","ALLR","BK4112","IE00B3QW5Z07.USD","BK4588","IE00BKPKM429.USD","LU0314104364.USD","SG9999014021.USD","NDAQ","BK4139","SG9999014013.SGD","BK4585","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014039.USD","LU2210150020.SGD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607822790","title":"Allarity Therapeutics Inc - on Jan 28, Co Entered Stock Purchase Agreement With Tumim Stone Capital - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2607822790","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607822790?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:50","pubTimestamp":1769691044,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nFWN3YU15O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607222082","title":"Allarity Therapeutics Inc - Company May Sell up to $6 Mln in Newly Issued Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2607222082","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607222082?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:50","pubTimestamp":1769691044,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nFWN3YU15O:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595977115","title":"Allarity Therapeutics Advances Stenoparib Toward FDA Approval After Strategic Realignment","url":"https://stock-news.laohu8.com/highlight/detail?id=2595977115","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595977115?lang=en_us&edition=fundamental","pubTime":"2025-12-31 21:00","pubTimestamp":1767186016,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics Inc. issued a business update in a letter to shareholders from CEO Thomas H. Jensen. The company reported significant progress in 2025, highlighting the advancement of its lead asset, stenoparib—a dual PARP and WNT pathway inhibitor—toward FDA approval for advanced ovarian cancer. Allarity also broadened the potential indications for stenoparib, including its application in recurrent small cell lung cancer and other difficult-to-treat cancers. The company emphasized strengthened financial foundations and continued clinical development. Looking ahead to 2026, Allarity plans to accelerate stenoparib’s path to approval, expand its indications, and explore additional growth opportunities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL1d427w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4585","BK4588","IE00BGHQF748.EUR","LU2095319765.USD","NDAQ","SG9999014013.SGD","SG9999014021.USD","BK4112","LU0314104364.USD","LU2210150020.SGD","LU2210149790.SGD","SG9999014005.SGD","ALLR","SG9999014039.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593608415","title":"Allarity Therapeutics Raises $2.5 Million in Private Placement of Unregistered Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593608415","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593608415?lang=en_us&edition=fundamental","pubTime":"2025-12-23 22:22","pubTimestamp":1766499739,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics Inc. has announced the completion of an additional closing of a private placement with an accredited investor, selling 255,103 shares of common stock at $0.98 per share, raising approximately $250,000 in gross proceeds. This transaction is part of a previously disclosed Securities Purchase Agreement, under which the company had earlier sold 1,562,500 shares and/or pre-funded warrants for gross proceeds of about $2.5 million. The shares were sold in an unregistered offering, relying on an exemption from registration under Section 4 of the Securities Act. Allarity Therapeutics intends to use the net proceeds for general corporate purposes and working capital.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL3hBXP4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589098356","title":"Allarity Therapeutics Sets New CFO Compensation Package With $367,700 Salary and $160,000 RSUs","url":"https://stock-news.laohu8.com/highlight/detail?id=2589098356","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589098356?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:17","pubTimestamp":1765203445,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics Inc. has entered into a new employment agreement with Chief Financial Officer Jeffrey S. Ervin, effective December 3, 2025. Under the agreement, Ervin will serve as CFO on a full-time basis with an annual base salary of $367,700. He will also receive restricted stock units valued at $160,000, subject to time-based vesting, and is eligible for an annual performance bonus of up to 30% of his base salary, contingent on individual and corporate objectives. If his employment is terminated without cause, for good reason, or in connection with a change of control, Ervin will receive six months of his final base salary as severance, paid as salary continuation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Thera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL3vHHn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588044174","title":"BRIEF-Allarity Therapeutics Inc - To Offer Up To $50 Million In Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2588044174","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588044174?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:12","pubTimestamp":1764771161,"startTime":"0","endTime":"0","summary":"BRIEF-Allarity Therapeutics Inc - To Offer Up To $50 Million In Securities Dec 3  - Allarity Therapeutics Inc ALLR.O:ALLARITY THERAPEUTICS INC - TO OFFER UP TO $50 MILLION IN SECURITIES - SEC FILINGSource text: [ID:n0001213900-25-117592]Further company coverage: ALLR.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X90FG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588044126","title":"Allarity Therapeutics Inc - to Offer up to $50 Mln in Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588044126","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588044126?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:12","pubTimestamp":1764771137,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X90FG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.allarity.com","stockEarnings":[{"period":"1week","weight":0.0085},{"period":"1month","weight":-0.0556},{"period":"3month","weight":-0.0165},{"period":"6month","weight":-0.2067},{"period":"1year","weight":0.6275},{"period":"ytd","weight":0.1019}],"compareEarnings":[{"period":"1week","weight":0.0412},{"period":"1month","weight":0.036},{"period":"3month","weight":-0.0111},{"period":"6month","weight":0.0315},{"period":"1year","weight":0.285},{"period":"ytd","weight":0.0061}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.137955},{"month":2,"riseRate":0,"avgChangeRate":-0.233915},{"month":3,"riseRate":0.4,"avgChangeRate":-0.236538},{"month":4,"riseRate":0.4,"avgChangeRate":-0.278967},{"month":5,"riseRate":0.25,"avgChangeRate":-0.092052},{"month":6,"riseRate":0.25,"avgChangeRate":-0.349039},{"month":7,"riseRate":0.25,"avgChangeRate":-0.205374},{"month":8,"riseRate":0.25,"avgChangeRate":0.045342},{"month":9,"riseRate":0.25,"avgChangeRate":-0.31064},{"month":10,"riseRate":0,"avgChangeRate":-0.290985},{"month":11,"riseRate":0,"avgChangeRate":-0.125579},{"month":12,"riseRate":0.25,"avgChangeRate":-0.118424}],"exchange":"NASDAQ","name":"Allarity Therapeutics Inc","nameEN":"Allarity Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Allarity Therapeutics Inc(ALLR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Allarity Therapeutics Inc(ALLR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Allarity Therapeutics Inc,ALLR,Allarity Therapeutics Inc股票,Allarity Therapeutics Inc股票老虎,Allarity Therapeutics Inc股票老虎国际,Allarity Therapeutics Inc行情,Allarity Therapeutics Inc股票行情,Allarity Therapeutics Inc股价,Allarity Therapeutics Inc股市,Allarity Therapeutics Inc股票价格,Allarity Therapeutics Inc股票交易,Allarity Therapeutics Inc股票购买,Allarity Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Allarity Therapeutics Inc(ALLR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Allarity Therapeutics Inc(ALLR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction